News

Filter

1 to 9 of 59 results

Samsung Bioepis' Enbrel biosimilar candidate SB4 accepted for review by EMA

Samsung Bioepis' Enbrel biosimilar candidate SB4 accepted for review by EMA

21-01-2015

South Korea’s Samsung Bioepis says that the Marketing Authorization Application for its Enbrel (etanercept)…

AmgenAnti-Arthritics/RheumaticsBiogen IdecBiosimilarsBiotechnologyEnbrelEuropePfizerRegulationSamsung Bioepis

New drugs and biosimilars to drive rheumatoid arthritis to $19.3 billion by 2023

New drugs and biosimilars to drive rheumatoid arthritis to $19.3 billion by 2023

13-01-2015

The launch of novel drugs and biosimilars will drive steady growth in the global rheumatoid arthritis…

AmgenAnti-Arthritics/RheumaticsEnbrelHumiraMarkets & MarketingPharmaceuticalResearchUSA

Sandoz fails in patent suit with Amgen over Enbrel; Cubist prevails over Cubicin

Sandoz fails in patent suit with Amgen over Enbrel; Cubist prevails over Cubicin

09-12-2014

US biotech giant Amgen saw its shares rise 1.9% to $172.00 yesterday after the top US patent appeal court…

AmgenAnti-Arthritics/RheumaticsAntibiotics and Infectious diseasesBiosimilarsCubicinCubist PharmaceuticalsEnbrelGenericsHospiraLegalNovartisPatentsSandozUSA

Xencor regains rights to XmAb5871 from Amgen

29-10-2014

US drug developer Xencor revealed yesterday that it has regained all development and commercial rights…

AmgenAnti-Arthritics/RheumaticsBiotechnologyImmunologicalsLicensingResearchXencorXmAb5871

Ph III study of Amgen’s Humira biosimilar ABP 501 meets endpoint in psoriasis

Ph III study of Amgen’s Humira biosimilar ABP 501 meets endpoint in psoriasis

09-10-2014

US biotech major Amgen says its Phase III study evaluating the efficacy and safety of its biosimilar…

AbbVieABP 501AmgenAnti-Arthritics/RheumaticsBiosimilarsBiotechnologyDermatologicalsHumiraResearchUSA

Amgen updates on Prolia in postmenopausal osteoporosis

Amgen updates on Prolia in postmenopausal osteoporosis

16-09-2014

USA-based Amgen has released results from a new exploratory analysis of the open-label extension study…

AmgenAnti-Arthritics/RheumaticsBiotechnologyProliaResearchWomen's Health

Premium-price biologicals and novel therapies will drive psoriatic arthritis market growth

10-09-2014

The market for psoriatic arthritis (PsA) therapies will grow nearly 66%, increasing to $3.7 billion in…

AbbVieAmgenAnti-Arthritics/RheumaticsBiosimilarsBiotechnologyEli LillyEuropeHumiraJapanMarkets & MarketingNovartisOtezlaStelaraUSAXeljanz

Daiichi Sankyo initiates testing of etanercept biosimilar in Japan

Daiichi Sankyo initiates testing of etanercept biosimilar in Japan

20-08-2014

Japanese drug major Daiichi Sankyo says it has started the Phase III trial of CHS-0214, an investigational…

Active rheumatoid arthritisAmgenAnti-Arthritics/RheumaticsBiosimilarsBiotechnologyCoherus BioSciencesDaiichi SankyoEnbreletanerceptJapanPharmacologyResearchRheumatoid arthritis

1 to 9 of 59 results

COMPANY SPOTLIGHT

Menarini

Back to top